BofA lowered the firm’s price target on Addus HomeCare (ADUS) to $140 from $147 and keeps a Buy rating on the shares. Following the company’s Q1 report, the firm maintains its EBITDA estimate, but applies a lower multiple to reflect lower peer group multiples.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADUS:
- Addus HomeCare Posts Strong Q1 Results, Expands into Indiana
- Addus HomeCare reports Q1 adjusted EPS $1.62, consensus $1.54
- Addus HomeCare sees ‘significant opportunities’ in 2026 for organic growth
- Addus HomeCare Corporation (ADUS) Q1 Earnings Cheat Sheet
- Buy Rating Maintained on Addus Homecare as Stable Costs and Operating Leverage Support $140 Price Target